Journal
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
Volume 17, Issue 17, Pages 2831-2843Publisher
IVYSPRING INT PUBL
DOI: 10.7150/ijms.40159
Keywords
Rapamycin; glioblastoma; mTOR signaling; mitochondrial dynamics; mitochondrial dysfunction; Temozolomide
Categories
Funding
- Golden LEAF Foundation
- National Natural Science Foundation of China [8156050251]
Ask authors/readers for more resources
Mammalian target of rapamycin (mTOR) is upregulated in a high percentage of glioblastomas. While a well-known mTOR inhibitor, rapamycin, has been shown to reduce glioblastoma survival, the role of mitochondria in achieving this therapeutic effect is less well known. Here, we examined mitochondrial dysfunction mechanisms that occur with the suppression of mTOR signaling. We found that, along with increased apoptosis, and a reduction in transformative potential, rapamycin treatment significantly affected mitochondrial health. Specifically, increased production of reactive oxygen species (ROS), depolarization of the mitochondrial membrane potential (MMP), and altered mitochondrial dynamics were observed. Furthermore, we verified the therapeutic potential of rapamycin-induced mitochondrial dysfunction through co-treatment with temzolomide (TMZ), the current standard of care for glioblastoma. Together these results demonstrate that the mitochondria remain a promising target for therapeutic intervention against human glioblastoma and that TMZ and rapamycin have a synergistic effect in suppressing glioblastoma viability, enhancing ROS production, and depolarizing MMP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available